Trials / Unknown
UnknownNCT01937832
A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 540 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 73 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and Efficacy of Faropenem in community-acquired pneumonia (CAP) subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Faropenem | dosage form: Injection dosage:1200 mg frequency: Three times a day |
| DRUG | Ertapenem | dosage form: Injection dosage:1000 mg frequency: once a day |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-10-01
- First posted
- 2013-09-10
- Last updated
- 2013-09-10
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01937832. Inclusion in this directory is not an endorsement.